Effects of implementation of an online comprehensive antimicrobial-stewardship program in ICUs: A longitudinal study  by Chen, I-Ling et al.
+ MODEL
Journal of Microbiology, Immunology and Infection (2016) xx, 1e9Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEEffects of implementation of an online
comprehensive antimicrobial-stewardship
program in ICUs: A longitudinal study
I-Ling Chen a,b, Chen-Hsiang Lee b,c,d,*, Li-Hsiang Su b,
Yu-Chin Lily Wang a, Jien-Wei Liu b,c,da Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
b Infection Control Team, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
c Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan
d Chang Gung University College of Medicine, Kaohsiung, TaiwanReceived 15 April 2016; received in revised form 26 May 2016; accepted 13 June 2016
Available online - - -KEYWORDS
antimicrobial
stewardship
program;
ICU;
patient outcomes;
quality improvement* Corresponding author. Department
Kaohsiung 833, Taiwan.
E-mail address: lee900@cgmh.org.
Please cite this article in press as: C
program in ICUs: A longitudinal s
j.jmii.2016.06.007
http://dx.doi.org/10.1016/j.jmii.2016
1684-1182/Copyright ª 2016, Taiwan S
BY-NC-ND license (http://creativecomAbstract Background/purpose: The long-term effects of antimicrobial-stewardship pro-
grams in the intensive care units (ICUs) have not been adequately examined. We evaluated
the impact of an online comprehensive antimicrobial stewardship program (OCASP) on the out-
comes of patients in 200-bed medical/surgical ICUs over the course of 11 years.
Methods: We analyzed the records of adult patients admitted to ICUs during the 5 years before
(n Z 27,499) and the 6 years after (n Z 33,834) implementation of an OCASP. Antimicrobial
consumption, expenditures, duration of treatment, incidence of healthcare-associated infec-
tions (HAIs), prevalence of HAIs caused by antimicrobial-resistant strains, and crude or sepsis-
related mortality of patients were analyzed. Segmented regression analyses of interrupted
time series were used to assess the significance of changes in antimicrobial use.
Results: Compared to the patients in the pre-OCASP period, the patients in the post-OCASP
period were older, had greater disease severity, longer ICU stays, and were more likely to
receive antimicrobials, but had lower antimicrobial expenditures and crude and sepsis-
related mortality. The trend of overall antimicrobial use [slope of defined daily dose/1000
patient-days vs. time) increased significantly before OCASP implementation (p < 0.001), but
decreased significantly after implementation (p < 0.01). The administration duration of all
classes of antibiotics were significantly shorter (p < 0.001) and the incidences of HAIs were
significantly lower (p < 0.001) after implementation. However, there was an increase in the
proportion of HAIs caused by carbapenem-resistant Acinetobacter baumannii relative to all
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The problem of increasing antimicrobial resistance is
especially critical for patients in the intensive care unit
(ICU), because they are more susceptible to healthcare-
associated infections (HAIs).1,2 Antibiotic resistance may be
particularly severe in ICUs, because the patients are criti-
cally ill and often severely immunocompromised, have un-
dergone medical or surgical procedures or instrumentation,
or receive multiple antimicrobials conferring selection
pressure of antimicrobial-resistant pathogens. Further-
more, effective infection-control programs may not be in
place.3 Previous research indicated that ICU patients are
five to 10 times more likely to acquire HAIs than patients in
general wards.4 Moreover, HAIs caused by antimicrobial-
resistant isolates are associated with increases of medical
costs, prolongation of ICU stays, and greater morbidity and
mortality.5 Several approaches may potentially reduce
antimicrobial resistance. For example, use of shorter
courses of broad-spectrum antimicrobials may reduce se-
lection pressure on bacterial flora and prevent the emer-
gence of resistance.6 In general, antimicrobial-stewardship
programs may help combat the emergence of antimicrobial
resistance, improve clinical outcomes, and reduce medical
costs by limiting the inappropriate use of antimicrobials.7,8
Previous research indicated that 30e50% of antimicro-
bial use in hospitals is unnecessary or inappropriate9 and
that, among all hospital departments, ICUs have the
greatest use of antimicrobials.1 Therefore, antimicrobial
stewardship is particularly important for ICU settings. Pre-
vious research examining the impact of antimicrobial
stewardship in ICUs indicated that changes in antimicrobial
use were associated with decreased antimicrobial resis-
tance.3,8,10 While implementation of an antibiotic stew-
ardship program requires considerable human resources,
especially in large institutions, the increased computeri-
zation of hospitals in recent years provided new opportu-
nities for development of such programs. A recent study in
a large hospital setting examined the impacts of an online,
comprehensive, facility-wide antimicrobial-control system
on healthcare quality and economic burden.11 However,
the long-term effects of computerized programs for
implementation of antimicrobial review in ICU patients
have not been adequately explored.
This longitudinal study reported the results of an online,
comprehensive, antimicrobial-stewardship program
(OCASP) implemented in 2005 that was developed to guide
the use of antimicrobial agents in the ICUs of a 2700-bed
medical center in southern Taiwan. The specific objectives
were to examine the long-term effects of OCASP on anti-
microbial use and expenditures, duration of antimicrobial
treatment, incidence of HAIs, prevalence of HAIs caused byhen I-L, et al., Effects of imple
tudy, Journal of Microbiology,antimicrobial-resistant pathogens, and outcomes of pa-
tients admitted to the ICUs.
Methods
Study design and setting
The Kaohsiung Chung Gang Memorial Hospital (KSCGMH) is a
medical center in southern Taiwan, with 2700 beds, 43 non-
critical wards, and 18 ICUs that included nine medical and
six surgical ICUs (a total of 200 beds) for adults. This
retrospective study was conducted with a waiver of the
need for informed consent of participants, and was
approved by the Institutional Review Board (Ethics Com-
mittee) of Chang Gung Memorial Hospital, Kaohsiung,
Taiwan (Document no. 97-1694B).
All data for patients aged 18 years or older who were
admitted to any medical or surgical ICU from January 2000
to December 2010 were retrospectively reviewed. The data
included age, sex, duration of ICU stay, use of parenteral
antimicrobials, and duration of antimicrobial treatment.
Disease severity was evaluated by Acute Physiology and
Chronic Health Evaluation (APACHE) II score12 or Glasgow
Coma Scale (GCS)13 upon ICU admission. All patients read-
mitted to an ICU after discharge were classified as new
patients.
OCASP in ICUs
The OCASP was implemented in the ICUs of the KSCGMH in
January 2005, wherein all antimicrobial agents prescribed
to ICU patients required approval from infectious diseases
(ID) physicians. The OCASP is built into the Health Infor-
mation System and is linked to comprehensive electronic
medical records. All inpatient settings were allocated and
preassigned to 10 ID physicians practicing in the hospital.
Each ID physician was notified when the antimicrobial was
prescribed to patients admitted to his or her preassigned
ICU or ward. All of the above information was entered into
OCASP automatically, and a remind message was sent to the
ID physician by mobile phone if the prescription was not
reviewed within 48 hours. The prescribing physicians were
required to provide necessary supporting clinical data that
included clinical history, laboratory reports, culture re-
sults, and images for online review by the ID physicians.
After review, the ID physicians would briefly discuss the
case with the intensivists prior to rendering a decision. If a
prescription was disapproved, the antimicrobial would be
discontinued by the pharmacy unit-dose delivery system
within 48 hours, and the prescriber would be immediately
notified to modify the regimen. When necessary, the IDmentation of an online comprehensive antimicrobial-stewardship
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patient evaluation was deemed necessary.
Measures of antimicrobial use, duration, and costs
The parenteral antimicrobials listed in the electronic
database of the hospital pharmacy were: carbapenems
group 1 (ertapenem), carbapenems group 2 (imipenem and
meropenem), non-extended-spectrum cephalosporins
(cefazolin, cefuroxime), extended-spectrum cephalospo-
rins (ceftriaxone, flomoxef, ceftazidime, cefpirome, and
cefepime), natural penicillin (penicillin G), amino-
penicillins (ampicillin and amoxicillin), antipseudomonal
penicillins (piperacillin and piperacillin-tazobactam), ami-
nopenicillins/b-lactamase inhibitor (amoxicillin/clav-
ulanate and ampicillin/sulbactam), aminoglycosides
(gentamicin and amikacin), fluoroquinolones (ciprofloxacin,
levofloxacin, and moxifloxacin), glycopeptides (vancomycin
and teicoplanin), other antibacterial agents (colistin, tige-
cycline, linezolid, daptomycin), and antifungal agents
(caspofungin, micafungin, voriconazole, and fluconazole).
Among these antimicrobial agents, ertapenem, levo-
floxacin, piperacillin-tazobactam, colistin, tigecycline,
linezolid, daptomycin, and micafungin were introduced to
the KSCGMH during the period following OCASP imple-
mentation. The other antimicrobial and antifungal agents
were available both before and after OCASP implementa-
tion. Consumption of each antimicrobial was expressed as
the defined daily dose (DDD) per 1000 inpatient days for
each prescribed antibiotic and the semester categorized
prescription to which the antibiotic belonged.14,15 The
duration of antibiotic administration was defined by the
start and stop dates. The costs of antimicrobial agents were
not standardized, because they changed significantly during
the 11-year study period. Expenditures were summed to
calculate the total cost of antimicrobials and/or pharma-
ceuticals. The expenditures of consumed antimicrobials
were calculated as a percentage of all pharmaceuticals
used during the ICU stay of the patient.
HAIs and the prevalence of HAIs caused by
antimicrobial resistance
HAIs, defined as infections that were not present and for
which there was no evidence of prior incubation at the time
of admission, were identified based on Centers of Disease
Control diagnostic criteria for nosocomial infections.16
There were no changes in microbiological laboratory
techniques during the 11-year study period. All isolated
microorganisms were identified using standard biochemical
tests and were verified by a Vitek System (bioMe´rieux,
Marcy-l’Etoile, France). Susceptibility testing was per-
formed following the guidelines of the Clinical Laboratory
Standards Institute (CLSI) for susceptibility testing, and the
results were interpreted according to the CLSI at the time
of the tests.17 Isolates with intermediate susceptibility
were considered resistant. The resistance of each antimi-
crobial agent was calculated as the number of
antimicrobial-resistant isolates divided by the total number
of tested pathogens. The prevalence of HAIs caused by
antimicrobial-resistant strains included carbapenemPlease cite this article in press as: Chen I-L, et al., Effects of imple
program in ICUs: A longitudinal study, Journal of Microbiology,
j.jmii.2016.06.007(represented by imipenem)-resistant Acinetobacter bau-
mannii (CRAB) and carbapenem (represented by
imipenem)-resistant Pseudomonas aeruginosa (CRPA).
End-point measurements
There were several end-points in this study. First, the total
consumption, expenditures, and durations of antimicrobial
use before and after OCASP implementation were
compared. Second, the incidence of HAIs and prevalence of
HAIs caused by antimicrobial-resistant pathogens during
ICU stays was assessed. Finally, the ICU readmission rate
was calculated as the number of patients who were read-
mitted to ICUs within 48 hours of discharge divided by the
number of patients who were discharged from ICUs. The
crude mortality was defined as the all-cause mortality
occurring during ICU stay. Sepsis-related mortality was
defined as death of a patient occurring within 14 days after
the onset of the sepsis, with a clinical course suggestive of
persistently active infection without other obvious
explanation.
Statistical analysis
Patient characteristics, expenditures for antimicrobials,
durations of antimicrobial treatments, and biannual HAI-
incidence rates before (from 1 January 2000 to 31
December 2004) and after (from 1 January 2005 to 31
December 2010) OCASP implementation were compared.
Categorical and continuous data are presented as a number
(percentage) and as a mean [95% confidence interval (CI)]
or median (inter-quartile range), respectively. Categorical
variables were compared with the Chi square test or the
Fisher’s exact test. Quantitative continuous variables were
compared using the t test or the ManneWhitney U test for
normally and non-normally distributed variables, respec-
tively. For multiple comparisons, p-values were calculated
by applying a Bonferroni correction. A segmented regres-
sion analysis of interrupted time series was used to assess
changes in antimicrobial consumption before and after
OCASP implementation. Autocorrelation must be consid-
ered in order to avoid bias in these estimates. In this study,
autocorrelation was measured using a Durbin-Watson test,
where values between 1.5 and 2.5 indicated no serial cor-
relation. We used a segmented linear regression model with
least squares fitting to estimate biannual antimicrobial
consumption in ICU patients:
Yt Z b0 þ b1  timet þ b2  policyt þ b3  time
aftert þ εt, (1)
where b0 was the mean baseline level of antimicrobial use
during the pre-OCASP period, b1 was the change in anti-
microbial use during the pre-OCASP period, b2 was the
mean antimicrobial use after OCASP implementation, b3
was the change in antimicrobial use after OCASP imple-
mentation, and εt represented an error term describing
random variability not explained by the model.18 All sta-
tistical analyses were performed using SAS software version
9.3 for Windows (SAS Institute Inc., Cary, NC, USA).mentation of an online comprehensive antimicrobial-stewardship
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Study population
There were 27,499 admissions before and 33,834 admis-
sions after OCASP implementation. Comparison of these
groups indicated that patients during the post-OCASP
period were older, had longer ICU stays, and were more
likely to have severe disease and receive antimicrobials
(Table 1).Antimicrobial consumption, treatment duration,
and expenditure
The numbers of ID physician disagreements with the
treating clinicians consisted of 2059 cases (35.2%) in 2005,
2123 cases (32.4%) in 2006, 2446 cases (30.6%) in 2007, 2739
cases (27.4%) in 2008, 2880 cases (28.5%) in 2009, and 3056
cases (29.8%) in 2010 (Figure 1). We analyzed the changes in
antimicrobial use (DDD) over time using segmental linear
regression of interrupted time series. The overall antimi-
crobial use (slope of DDD/1000 patient-days vs. time)
increased significantly before OCASP implementation
(p < 0.001), but decreased significantly after imple-
mentation (p < 0.01). We performed the same analysis for
individual classes of antimicrobials (Table 2). Consumption
of extended-spectrum cephalosporins, glycopeptides, car-
bapenem group 2, and aminopenicillins/b-lactamase in-
hibitors increased significantly before OCASP
implementation (p < 0.001 for all), but decreased signifi-
cantly after implementation (p < 0.05 for all). Consumption
of antifungal agents increased significantly before OCASPTable 1 Patient demographics, antibiotic expenditures, and cl
Before OCASP imple
(n Z 27,499)
Age, y 60.8 (60.6e61.0)
Gender, female/male 10,626/16,873
Length of intensive care units stay, d 4 (2e10)
ICU type
Medical 8830 (32)
Combined medical-coronary 3269 (12)
Combined medical-surgical 15,400 (56)
ICU re-admission rate 418 (1.5)
High disease severitya, A/B (%) 8973/14,743 (60.9)
Patients with antibiotics prescriptions 15,099 (54.9)
The expenditures of antibiotics among
all pharmaceuticals, %
49.0 (46.8e51.1)
Incidence of healthcare-associated
infections (events/1000
inpatient-days/6 months)a
15.1 (13.4e16.7)
Sepsis-related mortality, C/D (%) 2977/15,099 (19.7)
Crude mortality 5090 (18.5)
a High disease severity is defined as patients with APACH II scores >
Data are presented as n (%), or median (inter-quartile range), or mea
*Because of the large patient sample, we defined statistical significa
AZ number of patients; BZ number of patients with available data; C
of patients with sepsis; ICU Z intensive care unit; OCASP Z online c
Please cite this article in press as: Chen I-L, et al., Effects of imple
program in ICUs: A longitudinal study, Journal of Microbiology,
j.jmii.2016.06.007implementation (pZ 0.04), but did not change significantly
after implementation (p Z 0.42). Consumption of anti-
pseudomonal penicillins did not change significantly before
OCASP implementation (p Z 0.33), but increased signifi-
cantly after implementation (p < 0.01). Consumption of
nonextended-spectrum cephalosporins (p Z 0.04) and
aminoglycosides (p < 0.001) decreased significantly before
OCASP implementation, but did not change significantly
after implementation. The consumption trend of fluo-
roquinolones and natural penicillin/aminopenicillins did not
change significantly during either period. Comparison of the
intercepts of the time series indicated positive values for
overall antimicrobial use and for each class of antimicrobial
and antifungal agents before OCASP implementation
(p < 0.05 for all; Table 2). After OCASP implementation,
most of the individual drug classes exhibited no significant
changes in the intercepts; however, there were significant
decreases in the intercepts associated with antifungal
agents (p Z 0.02), natural penicillin/aminopenicillins
(p Z 0.02), antipseudomonal penicillins (p < 0.01), and
glycopeptides (p < 0.001), but there was a significant in-
crease in the intercept associated with aminopenicillins/b-
lactamase inhibitors (p < 0.01).
We also analyzed the effect of the OCASP on the
duration of antimicrobial administration (Table 3). Anal-
ysis of the individual drug classes of antimicrobials indi-
cated that all classes of antimicrobial-treatment
durations were significantly shorter (p < 0.001) after
OCASP implementation, except that the treatment
duration of antifungal agents did not differ between the
two time periods (p Z 0.05). The antimicrobial expen-
ditures as a percentage of all pharmaceuticals [mean
(95% CI)] were significantly less after OCASPinical outcomes before and after OCASP implementation.
mentation After OCASP implementation
(n Z 33,834)
p*
62.0 (61.8e62.2) < 0.001
12,955/20,879 0.37
5 (2e11) < 0.001
< 0.001
11,924 (35)
3336 (10)
18,575 (55)
372 (1.1) < 0.001
15,687/23,089 (67.9) < 0.001
20,366 (60.2) < 0.001
42.7 (41.6e43.8) < 0.001
11.0 (10.3e11.8) <0.001
3360/20,366 (16.5) < 0.001
5037 (14.9) < 0.001
15 or Glasgow Coma Scales <9.
n (95% confidence interval).
nce as p < 0.001.
Z number of patients with sepsis-related mortality; DZ number
omprehensive antimicrobial stewardship program.
mentation of an online comprehensive antimicrobial-stewardship
Immunology and Infection (2016), http://dx.doi.org/10.1016/
Figure 1. The main coordinate: overall use of antimicrobials (DDDs/1000 patient-days/6 months) before and after OCASP
implementation. The second coordinate: the proportion of disagreement percentage (%) after OCASP implementation.
DDD Z defined daily dosage; OCASP Z online comprehensive antimicrobial stewardship program.
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(41.6e43.8)%, p < 0.001; Table 1].
Quality indicators
The ICU re-admission rate and incidence of HAIs in the
ICUs were significantly lower after OCASP implementation
(p < 0.001; Table 1). The crude mortality rate (18.5% vs.
14.9%; p < 0.001) and sepsis-related mortality rate (19.7%
vs. 16.5%; p < 0.001) were both significantly reduced after
OCASP implementation (Table 1). However, after imple-
mentation, there was an increase in the proportion of HAIs
caused by CRAB relative to all A. baumannii (CRABpAB)
and a decrease in the proportion of HAIs caused by CRPA
relative to all P. aeruginosa (CRPApPA; Figure 2). Specif-
ically, the percentage of CRABpAB infections was 0% in the
first half of 2000, 72.7% in the second half of 2007, and
61.5% in the second half of 2010. The percentage of
CRPApPA infections was 10.3% in the first half of 2000,
38.9% in the first half of 2004, and 25.9% in the second half
of 2010.
Discussion
Appropriate and judicious antimicrobial use guided by an
OCASP can be associated with significant benefits by
reducing antimicrobial consumption and expenditure while
not compromising healthcare quality in ICU settings. Recent
epidemiological data indicate an increasing frequency and
awareness of HAIs by antimicrobial-resistant pathogens,
especially in ICUs,1,2,19 that significantly impact clinical
outcomes and economic expenditures.5,20 Antimicrobial-
stewardship programs employ diverse interventions to
improve the selection of appropriate antimicrobial agents,
dosing, and duration of therapy, and simultaneously seek toPlease cite this article in press as: Chen I-L, et al., Effects of imple
program in ICUs: A longitudinal study, Journal of Microbiology,
j.jmii.2016.06.007improve clinical outcomes and limit the emergence of
antimicrobial resistance of pathogenic organisms, adverse
drug events, and other negative consequences.21 In a sys-
tematic review of the effectiveness of antimicrobial stew-
ardship in ICUs, Kaki et al8 suggested that most stewardship
interventions were associated with a temporal decrease in
either targeted or overall antibiotic use in critically ill pa-
tients. However, restricting the use of certain antimicrobial
classes may be associated with a compensatory increase in
the use of unrestricted antimicrobials, a phenomenon
called “squeezing the balloon”.22 Furthermore, previous
studies of antimicrobial-stewardship programs did not
provide details about their effects on the incidence of HAIs,
length of ICU stays, or mortality, and few studies demon-
strated the long-term effectiveness of such programs.8 To
our knowledge, this study is the first to demonstrate that
long-term implementation of an OCASP at a large institu-
tion significantly reduced antimicrobial use and expendi-
tures without having adverse effects on healthcare quality.
The increasing duration of ICU stays in our post-
implementation period may be explained by the greater
number of patients with more severe illnesses during this
period. The increases in the intercept of consumption of
aminopenicillins/b-lactamase inhibitors (amoxicillin/clav-
ulanate and ampicillin/sulbactam), but decreases in the
trend of consumption of aminopenicillins/b-lactamase in-
hibitors after OCASP implementation were probably due to
OCASP-related de-escalation of empiric broad-spectrum
antimicrobials to narrow-spectrum antimicrobials, such as
aminopenicillins/b-lactamase inhibitors and use of ampi-
cillin/sulbactam for CRAB infection, that reduced the sub-
sequent consumption of this class of antimicrobials.
Therefore, the most striking changes in trends after
implementation of our OCASP were the reduced consump-
tion of broad-spectrum antimicrobials. The increasing trend
of consumption of antipseudomonal penicillins after OCASPmentation of an online comprehensive antimicrobial-stewardship
Immunology and Infection (2016), http://dx.doi.org/10.1016/
Table 2 Trends in the use of antibiotics (DDD/1,000 patients days/6 months) before and after OCASP implementation.
Significant parameters of segmented regression analysis, coefficient size, & direction of effect (95% CI) R2 DW
Before OCASP implementation After OCASP implementation
Intercept p* Slope p* Change in intercept p* Change in slope p*
Non-extended-spectrum
cephalosporins
214.6 (199.2~230.1) < 0.001 2.62 (5.1~0.1) 0.04 5.7 (25.0~13.5) 0.54 2.3 (5.4~0.8) 0.14 0.89 2.0
Aminoglycosides 205.1 (194.0~215.1) < 0.001 10.2 (11.9~8.6) < 0.001 0.1 (12.9~12.7) 0.98 3.8 (1.8~5.9) 0.18 0.98 2.2
Extended-spectrum
cephalosporins
88.1 (57.5~114.6) < 0.001 11.7 (7.1~16.3) < 0.001 3.19 (32.6~38.73) 0.85 59.5 (15.3~3.73) 0.03 0.82 1.7
Fluoroquinolones 27.6 (13.8~41.4) < 0.001 2.1 (0.1~4.3) 0.06 6.4 (10.8~23.6) 0.44 1.4 (1.4~4.2) 0.30 0.83 1.6
Glycopeptides 32.1 (19.9~44.3) < 0.001 9.6 (7.7~11.6) < 0.001 31.5 (46.6~16.3) < 0.001 6.2 (8.7~3.8) < 0.001 0.92 1.6
Natural penicillin/
aminopenicillins
124.0 (109.4~139.2) < 0.001 0.6 (1.8~3.0) 0.6 22.5 (41.1~3.9) 0.02 6.3 (9.3~3.2) 0.16 0.90 1.8
Antipseudomonal
penicillins
52.1 (43.4~60.8) < 0.001 0.67 (2.07~0.73) 0.33 14.6 (25.5~3.76) 0.01 3.3 (1.6~5.1) < 0.01 0.55 1.6
Carbapenem group 2 17.2 (4.2~30.2) 0.01 8.7 (6.7~10.9) < 0.001 9.2 (25.4~7.1) 0.25 7.5 (10.1~4.8) < 0.001 0.90 1.7
Aminopenicillins/
b-lactamase
inhibitors
29.1 (4.4~53.8) 0.02 7.9 (3.9~11.9) < 0.001 44.8 (14.0~75.6) < 0.01 11.3 (16.3~6.3) < 0.001 0.82 1.6
Antifungal agents 60.1 (49.3~70.8) < 0.001 1.8 (0.1~3.5) 0.04 16.2 (29.6~2.8) 0.02 0.8 (3.1~1.3) 0.42 0.29 1.7
Overall antimicrobials 949.1 (873.0~1024.1) < 0.001 24.5 (12.3~36.7) < 0.001 39.3 (133.5~54.8) 0.40 23.5 (38.8~8.2) < 0.01 0.60 1.8
* The p-values represent comparisons in the time periods before or after implementation of the OCASP program, with p < 0.05 representing statistical significance.
CI Z confidence interval; DDD Z defined daily dose; DW Z Durbin-Watson test; OCASP Z online comprehensive antimicrobial stewardship program.
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Table 3 Treatment durations for different classes of antimicrobials before and after OCASP implementation.
Before OCASP implementation After OCASP implementation p*
Median (IQR, d) Median (IQR, d)
Aminoglycosides 3 (2e6) 3 (1e4) < 0.001
Extended-spectrum cephalosporins 5 (2e10) 5 (2e8) < 0.001
Fluoroquinolones 6 (2e10) 4 (2e8) < 0.001
Glycopeptides 5 (2e10) 4 (2e8) < 0.001
Natural penicillin/aminopenicillins 4 (2e7) 3 (1e6) < 0.001
Antipseudomonal penicillins 5 (2e9) 4 (2e8) < 0.001
Carbapenem groups 1 and 2 7 (3e12) 5 (2e10) < 0.001
Non-extended-spectrum cephalosporin 3 (2e5) 3 (1e4) < 0.001
Aminopenicillins/b-lactamase inhibitors 4 (2e8) 4 (2e7) < 0.001
Antifungal agents 6 (3e11) 6 (3e11) 0.05
* The p values were estimated following multiple comparisons and were corrected by Bonferroni correction; p < 0.005 was considered
significant.
IQR Z inter-quartile range; OCASP Z online comprehensive antimicrobial stewardship program.
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tazobactam being introduced in our intuition during the
post-implementation period.
Our results indicated that the duration of individual
classes of antimicrobial use decreased during the post-
implementation period (Table 3). Specifically, the duration
of broad-spectrum antimicrobial use [extended-spectrum
cephalosporins, fluoroquinolones, antipseudomonal peni-
cillins, and carbapenems (Groups 1 and 2)] was shorter
during the post-implementation period, even though the
patients were more likely to have severe disease during this
period. After implementation of our OCASP, intensivists
prescribed shorter courses of broad-spectrum antimicrobial
treatment and/or de-escalated use of empirical broad-
spectrum antimicrobials.
One end-point of our study involved estimation of OCASP
impact on healthcare quality. Lowering ICU mortality re-
quires optimization of ICU-service organization. IntensivistsFigure 2. Percentage of HAIs caused by CRAB relative to all AB
mentation. AB Z Acinetobacter baumannii; CRAB Z carbapene
resistant Pseudomonas aeruginosa; HAI Z healthcare-associated i
ardship program; PA Z Pseudomonas aeruginosa.
Please cite this article in press as: Chen I-L, et al., Effects of imple
program in ICUs: A longitudinal study, Journal of Microbiology,
j.jmii.2016.06.007adopted the surviving ICU campaign in 2009 in response to
the “international guidelines for management of severe
sepsis and septic shock”.23 Infection-control nurses dedi-
cated to the hand-hygiene program, care bundle, moni-
toring, and inspection of patients infected with resistant
pathogens also contributed greatly to reducing the HAI
rate. Pharmacists periodically monitored the consumption
and expenditure of antimicrobial agents among different
departments. Clinical microbiologists provided prompt data
on organism identification and pathogen-susceptibility
patterns. Treating clinicians can still preserve prescriber
autonomy and provide opportunities for education and
collaboration through audit and feedback to optimize the
use of antimicrobials. As a result, the proportions of ID
physician disagreement with the treating clinicians
decreased over the 6 months following OCASP imple-
mentation (Figure 1). We believe that multidisciplinary
teamwork along with OCASP implementation was the key toand by CRPA relative to all PA before and after OCASP imple-
m-resistant Acinetobacter baumannii; CRPA Z carbapenem-
nfection; OCASP Z online comprehensive antimicrobial stew-
mentation of an online comprehensive antimicrobial-stewardship
Immunology and Infection (2016), http://dx.doi.org/10.1016/
8 I.-L. Chen et al.
+ MODELthe success of the ASP in terms of both process and
outcome measurements. In this study, consumption and
expenditure of antimicrobial agents in adult ICUs decreased
after OCASP implementation without compromising
healthcare quality.
Many factors other than antimicrobial-consumption
patterns can potentially affect the number and resis-
tance patterns of bacteria identified from clinical isolates.
Despite the remarkable reduction in the use of antimi-
crobials after OCASP implementation, we noted a persis-
tently high prevalence of CRAB and CRPA in our ICUs,
despite the lack of increased CRAB or CRPA prevalence in
any clinical wards or ICUs during the study period. It is
possible that inappropriate carbapenem prescriptions
might increase selection pressure for carbapenem-
resistant bacteria.24e26 The use and duration of carbape-
nem therapy in our ICU patients decreased during the post-
implementation period, and, accordingly, the percentage
of CRPApPA reached its peak during the pre-OCASP period,
but decreased before OCASP implementation, with no in-
creases in percentages after OCASP implementation
(Figure 2). However, the percentage of CRABpAB increased
throughout the entire study period. This might be because
many of our patients were transferred from other health-
care institutions, which did not have antimicrobial-
stewardship programs. Additionally, the global incidence
of CRAB increased steadily during the 2000s,27 and a recent
longitudinal multicenter surveillance program in Taiwan
indicated a significant increase in CRAB over the past
10 years.28 The proportion of CRABpAB detection in ICU
settings increased from < 10% of infections in 2002 to >
70% in 2010.25 Given the commonality of risk factors for all
drug-resistant microbes,29 this supports the importance of
implementation of an OCASP with strict infection-control
measures to reduce the secondary spread of resistant or-
ganisms within ICUs.
A limitation of this study, as with other longitudinal
uncontrolled studies that compare the effect of a newly
introduced control measure, was that confounding factors
may not have been adequately considered. There was no
randomized allocation of stewardship intervention to
different ICUs, and, therefore, we could not determine
whether the changes observed were the consequences of or
merely coincident with implementation of the OCASP.
While randomization is not possible, bias can be minimized
with the use of time-series analysis with multiple mea-
surements during each time period as performed here. We
could measure the inappropriateness of antimicrobial use,
which was represented by the proportion of ID physician
disagreements with the treating clinicians after OCASP
implementation. Furthermore, we measured antimicrobial
use and average duration of therapy. We did not consider
the number of antimicrobial courses and did not focus on
antimicrobials used to treat specific conditions, such as
urinary tract infection or pneumonia. This limited our
ability to comment on the appropriateness of the average
antimicrobial treatment. Nevertheless, the duration of
broad-spectrum antimicrobial use was shorter during the
post-implementation period. Other interventions, such as
improved hand hygiene and staff education,30 may have
confounded these results; however, these interventions
were mainly instituted in our ICUs.Please cite this article in press as: Chen I-L, et al., Effects of imple
program in ICUs: A longitudinal study, Journal of Microbiology,
j.jmii.2016.06.007In summary, the results of this study indicated that
OCASP provided a sustainable system for antimicrobial
stewardship. In particular, the ICUs of a large medical fa-
cility indicated that an OCASP could effectively reduce the
use of antimicrobials, lower antimicrobial expenditures,
and shorten the duration of broad-spectrum antimicrobial
therapy while exhibiting no detrimental effects on health-
care quality.Conflicts of interest
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